

Date: October 27, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip code: 544292	The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai – 400 051 Scrip code: ONESOURCE
--	---

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Designation of Dr. Claudio Albrecht (DIN: 10109819) from Independent Director to Non-Executive Non-Independent Director

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., October 27, 2026, based on the recommendation of the Nomination and Remuneration Committee, has approved the change in designation of Dr. Claudio Albrecht (DIN: 10109819) from Independent Director to Non-Executive Non-Independent Director of the Company, subject to the approval of the shareholders of the Company.

The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 (as amended from time to time) are enclosed as Annexure A.

The meeting of the Board of Directors commenced at 09:00 hrs (IST) and concluded at 10:00 hrs (IST).

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Digitally signed by Trisha A
Date: 2026.10.27 10:01:22
+05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl: Annexure A

Annexure A

Particulars	Details
Reason for change viz. ~~appointment/re-appointment/~~ ~~resignation/removal/death or~~ otherwise	Change in designation from Independent Director to Non-Executive Non-Independent Director
Date of ~~appointment/re-~~ ~~appointment/cessation/~~ (as ~~applicable~~) & term of ~~appointment/re-appointment/~~ change in designation	October 27, 2026
Effective date of change	October 27, 2026
Term of appointment	Dr. Claudio Albrecht shall continue as a Non-Executive Non-Independent Director of the Company, subject to approval of shareholders and liable to retire by rotation in accordance with the Companies Act, 2013 and Articles of Association of the Company.
Brief Profile	Dr. Claudio Albrecht is Co-Founder and Managing Partner of Albrecht, Prock & Partners AG, a Zug-based strategic advisory firm focused on pharmaceutical acquisitions and investments. With over three decades of experience in generics industry, he has served as CEO of Ratiopharm Group, Actavis Group and STADA AG. He began his career at Sandoz and later led generics operations across the Netherlands, Germany, and the United States. As CEO of Ratiopharm Group, he led its international expansion and initiated its biosimilars programme. He co-founded CoMeth and later led Actavis through a major turnaround, culminating in its US\$6 billion sale to Watson. He also played a key role in the leveraged buyout of STADA AG and in developing a comprehensive diabetes generics platform.
Disclosure of relationship between Directors (in case of appointment of a director)	Dr. Claudio Albrecht is not related to any Director of the Company.
Information as required pursuant to BSE Circular No. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CML/2018/24 dated June 20, 2018	Dr. Claudio Albrecht is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other statutory authority.